Drug intelligence / Profile preview

Viravaxx HIV vaccine

Development stage: Preclinical
Lead developer: Viravaxx
Modality: Peptides, Vaccines & Immunotherapeutics

Overview

Viravaxx is developing a preclinical HIV vaccine candidate using its proprietary PCFiT (Peptide-Carrier Fusion Technology) platform. Developed in collaboration with the Medical University of Vienna, the platform converts non-immunogenic epitopes of viral surface proteins into potent immunogens. The vaccine is designed to elicit protective antibody and T-cell immune responses against HIV, targeting both the prevention and treatment of HIV/AIDS. The technology focuses on epitopes essential for the virus life cycle to ensure a robust and relevant immune response.

Other names: HIV vaccine candidate (Viravaxx)

Targets

gp41 (Human immunodeficiency virus type 1 glycoprotein 41)

Beyond the preview

Go deeper on Viravaxx HIV vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viravaxx HIV vaccine.

Explore the full profile